Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

161. Medicines used for Multiple Sclerosis A Health

Medicines used for Multiple Sclerosis A Health Medicines used for Multiple Sclerosis. A Health - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Medicines used for Multiple Sclerosis. A Health Have you found an error? Order Download: Key message This Health Technology Assessment (...) was commissioned by the “National system for the introduction of new health technologies within the specialist health service”. The aim of this report was to assess the effect and cost-effectiveness of the disease modifying medicines used in Norway for patients with relapsing remitting multiple sclerosis (dimethyl fumarate, teriflunomide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fingolimod, and alemtuzumab). The key results are: • We identified 37 randomised clinical trials

2016 Norwegian Institute of Public Health

162. Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients

Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Electric Stimulation; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Peroneal Neuropathies Language Published English Country of organisation United States English summary An English language summary is available. Address

2015 Health Technology Assessment (HTA) Database.

163. Sodium channel blockers for neuroprotection in multiple sclerosis. (Abstract)

Sodium channel blockers for neuroprotection in multiple sclerosis. Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating disease of the central nervous system (CNS), which can occur in many parts of the CNS and result in a wide range of symptoms including sensory impairment, fatigue, walking or balance problems, visual impairment, vertigo and cognitive disabilities. At present, the most commonly used MS treatments are immunomodulating agents, but they have little effect (...) strategy for preventing disability progression in people with MS.To assess the efficacy and safety of sodium channel blockers for neuroprotection in people with MS to prevent the occurrence of disability and alleviate the burden of the disease.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (27 August 2015) which, among other sources, contains references from the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane

2015 Cochrane

164. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Full Text available with Trip Pro

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders.We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing (...) -remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 μg once weekly, for up to 144 weeks. The primary end point was the annualized relapse rate.The annualized relapse rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with daclizumab HYP; P<0.001). The number of new or newly enlarged hyperintense lesions on T2-weighted

2015 NEJM Controlled trial quality: predicted high

165. Exercise therapy for fatigue in multiple sclerosis. Full Text available with Trip Pro

Exercise therapy for fatigue in multiple sclerosis. Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system affecting an estimated 1.3 million people worldwide. It is characterised by a variety of disabling symptoms of which excessive fatigue is the most frequent. Fatigue is often reported as the most invalidating symptom in people with MS. Various mechanisms directly and indirectly related to the disease and physical inactivity have been proposed to contribute (...) to the degree of fatigue. Exercise therapy can induce physiological and psychological changes that may counter these mechanisms and reduce fatigue in MS.To determine the effectiveness and safety of exercise therapy compared to a no-exercise control condition or another intervention on fatigue, measured with self-reported questionnaires, of people with MS.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Trials Specialised Register, which, among other sources

2015 Cochrane

166. The effectiveness of behaviour change interventions to increase physical activity participation in people with multiple sclerosis: A systematic review and meta-analysis (Abstract)

The effectiveness of behaviour change interventions to increase physical activity participation in people with multiple sclerosis: A systematic review and meta-analysis A systematic review and meta-analysis was conducted to illustrate whether people with multiple sclerosis engage in more physical activity following behaviour change interventions.MEDLINE, CINAHL, PubMed, Web of Sciences, Cochrane Library, SCOPUS, EMBASE and PEDro were searched from their inception till 30 April 2015.Randomized (...) and clinical controlled trials that used behaviour change interventions to increase physical activity in people with multiple sclerosis were selected, regardless of type or duration of multiple sclerosis or disability severity.Data extraction was conducted by two independent reviewers and the Cochrane Collaboration's recommended method was used to assess the risk of bias of each included study.A total of 19 out of 573 studies were included. Focusing on trials without risk of bias, meta-analysis showed

2015 EvidenceUpdates

167. Peginterferon beta-1a (Plegridy) - for the treatment of relapsing remitting multiple sclerosis

Peginterferon beta-1a (Plegridy) - for the treatment of relapsing remitting multiple sclerosis Final Appraisal Recommendation Advice No: 1615 – June 2015 Peginterferon beta-1a (Plegridy ® ? ) 63 micrograms, 94 micrograms and 125 micrograms solution for injection in pre-filled pen Submission by Biogen Idec Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2013), which includes the AWMSG Secretariat (...) in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1615: Peginterferon beta-1a (Plegridy ® ? ) 63 micrograms, 94 micrograms and 125 micrograms solution for injection in pre-filled pen. June 2015. Recommendation of AWMSG Peginterferon beta-1a (Plegridy ® ? ) is recommended as an option for use within NHS Wales in adult patients for the treatment of relapsing remitting multiple sclerosis.

2015 All Wales Medicines Strategy Group

168. Effect of comorbidity on mortality in multiple sclerosis Full Text available with Trip Pro

Effect of comorbidity on mortality in multiple sclerosis We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations.Using population-based administrative data, we identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and region. We estimated annual mortality rates. Using Cox proportional hazards regression, we evaluated

2015 EvidenceUpdates

169. Guidelines for prescribing disease-modifying treatments in multiple sclerosis

Guidelines for prescribing disease-modifying treatments in multiple sclerosis Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Neil Scolding, 1 David Barnes, 2 Sarah Cader, 3 Jeremy Chataway, 4 Abhijit Chaudhuri, 5 Alasdair Coles, 6 Gavin Giovannoni, 7 David Miller, 8 Waqar Rashid, 9 Klaus Schmierer, 10 Abdullah Shehu, 11 Eli Silber, 12 Carolyn Young, 13 John Zajicek 14 ? Additional material is published online (...) -001139 INTRODUCTION In June 1999, the Association of British Neurologists (ABN) first published guide- lines for the use of the licensed multiple sclerosis (MS) disease-modifying treat- ments (at that time ß-interferon and gla- tiramer acetate). The guidelines were revised in 2001 and have been periodic- ally updated since then. In 2002, follow- ing the negative assessment of these treatments by the National Institute for Health and Care Excellence (NICE), the MS risk-sharing scheme started, in which

2015 Association of British Neurologists

170. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis

Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 150. 2015 Authors' objectives We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long

2015 Health Technology Assessment (HTA) Database.

171. Telerehabilitation for persons with multiple sclerosis. (Abstract)

Telerehabilitation for persons with multiple sclerosis. Telerehabilitation, an emerging method, extends rehabilitative care beyond the hospital, and facilitates multifaceted, often psychotherapeutic approaches to modern management of patients using telecommunication technology at home or in the community. Although a wide range of telerehabilitation interventions are trialed in persons with multiple sclerosis (pwMS), evidence for their effectiveness is unclear.To investigate the effectiveness (...) and safety of telerehabilitation intervention in pwMS for improved patient outcomes. Specifically, this review addresses the following questions: does telerehabilitation achieve better outcomes compared with traditional face-to-face intervention; and what types of telerehabilitation interventions are effective, in which setting and influence which specific outcomes (impairment, activity limitation and participation)?We performed a literature search using the Cochrane Multiple Sclerosis and Rare Diseases

2015 Cochrane

172. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use (...) in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2015 Health Technology Assessment (HTA) Database.

173. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial Full Text available with Trip Pro

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS).Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy

2015 EvidenceUpdates Controlled trial quality: uncertain

174. Multiple sclerosis: neither natalizumab nor alemtuzumab

Multiple sclerosis: neither natalizumab nor alemtuzumab Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: neither natalizumab nor alemtuzumab'', 1 March 2015 {1} {1} {1} | | > > > Multiple sclerosis: neither natalizumab nor alemtuzumab Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: neither natalizumab nor alemtuzumab (...) With the benefit of hindsight, natalizumab (Tysabri°) has proved even more toxic than expected in multiple sclerosis patients. Evaluation of alemtuzumab (Lemtrada°) is too biased for its potential usefulness to be judged, however it exposes patients to severe adverse effects. The reference treatment for relapsing-remitting multiple sclerosis which progresses in flare-ups is interferon beta injection, for lack of anything better. In 2007, in severe multiple sclerosis when interferon beta does not seem

2015 Prescrire

175. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Full Text available with Trip Pro

Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Case reports have suggested a link between human papillomavirus (HPV) vaccination and development of multiple sclerosis and other demyelinating diseases.To investigate if quadrivalent HPV (qHPV) vaccination is associated with an increased risk of multiple sclerosis and other demyelinating diseases.Using nationwide registers we identified a cohort of all females aged 10 (...) years to 44 years in Denmark and Sweden, followed up from 2006 to 2013, information on qHPV vaccination, and data on incident diagnoses of multiple sclerosis and other demyelinating diseases. The primary analysis used a cohort design including vaccinated and unvaccinated study participants. A secondary analysis used a self-controlled case-series design including only cases. Both analyses used a 2-year risk period following vaccination.Information on qHPV vaccination was obtained through the national

2015 JAMA

176. Management of Multiple Sclerosis

Management of Multiple Sclerosis Management of Multiple Sclerosis Published by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to MaHTAS is included (...) of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. A multidisciplinary team will be formed and the latest systematic review methodology used by MaHTAS will be employed. Management of Multiple Sclerosis TABLE OF CONTENTS No. Title Page Levels of Evidence & Formulation of Recommendation i Guidelines Development and Objectives ii Guidelines Development Group v Review Committee vi External Reviewers vii Algorithm 1

2015 Ministry of Health, Malaysia

177. Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Full Text available with Trip Pro

Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis Article Text Therapeutics/Prevention Randomised controlled trial Cannabinoids fail to show evidence

2015 Evidence-Based Medicine

178. Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line

Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for primary (...) and secondary progressive multiple sclerosis - first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase

2015 Health Technology Assessment (HTA) Database.

179. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses - add on therapy to current immunomodulators

Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses - add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty

2015 Health Technology Assessment (HTA) Database.

180. Natalizumab (Tysabri) for secondary progressive multiple sclerosis

Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Natalizumab (Tysabri) for secondary progressive multiple sclerosis. Birmingham: NIHR Horizon (...) Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Natalizumab (Tysabri) is intended for the treatment of secondary progressive multiple sclerosis (SPMS) in patients who have progressed from relapsing remitting MS. If licensed, natalizumab will offer an additional treatment option for patients with SPMS, a group who currently have few effective therapies available. No disease-modifying drugs are currently licensed specifically for SPMS. Natalizumab is a selective

2015 Health Technology Assessment (HTA) Database.